GM-2505 is under clinical development by Gilgamesh Pharmaceuticals and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GM-2505’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GM-2505 overview
GM-2505 is under development for the treatment of major depressive disorder, anxiety and other psychiatric disorders. The therapeutic candidate is a short acting psychoactive compound which acts by targeting 5-hydroxytryptamine receptor 2A (HTR2A) and is being developed based on AI-powered ENKIDU platform. It is administered through intravenous route.
Gilgamesh Pharmaceuticals overview
Gilgamesh is a serious mental health science focused, preclinical biotechnology company. The company has a disciplined focus on developing innovative new chemical entities (NCE’s) leveraging a combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise.
For a complete picture of GM-2505’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
